Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Neurobiol Dis. 2006 Dec 29;26(1):201–211. doi: 10.1016/j.nbd.2006.12.011

Figure 7.

Figure 7

D2 dopamine receptor mediated responses. A, Control and coloboma mice (n = 11–12/genotype/dose) were injected with the D2-like dopamine receptor antagonist spiperone. Catalepsy was assessed every 20 min for 2 hr. Data represent average catalepsy time from the 6 test intervals and are expressed as mean ± SEM. Two-factor ANOVA with repeated measures revealed main effects of genotype (F1,18 = 5.28, p < 0.05) and dose (F5,90 = 17.37, p < 0.0001). B, Control and coloboma mice (n = 8/genotype/dose) were challenged with the D2/D3 dopamine receptor-selective agonist quinpirole and locomotor activity was assessed. Data are presented as percent of vehicle treatment to normalize for gross differences in baseline locomotor activity and are expressed as mean ± SEM. Two-factor ANOVA with repeated measures revealed main effects of genotype (F1,14 = 6.24, p < 0.05) and dose (F4,56 = 4.18, p < 0.01). C, Quinpirole-mediated inhibition of 0.1 μM forskolin-stimulated adenylate cyclase activity. Data are expressed as a percent of forskolin-induced adenylate cyclase activity without agonist. Data represent mean ± SEM (n = 8/genotype). Two-factor ANOVA with repeated measures revealed main effects of genotype (F1,14 = 5.65, p < 0.05) and dose (F2,28 = 4.73, p < 0.05).